Sysmex Corporation responded to a call by the Japan International Cooperation Agency (JICA) for proposals under the second fiscal 2017 Collaboration Program with the Private Sector for Disseminating Japanese Technology for Social and Economic Development of Developing Countries. Sysmex’s proposal “Dissemination of Automated Urinalysis Diagnosis technology in the Republic of Ghana” was selected.
Sysmex Corporation announces its accreditation under the international standard ISO Guide 34 (General requirements for the competence of reference material producers). It is important for laboratories to ensure traceability, in order to ensure the quality of their test results. Laboratories ensure traceability through routine calibration and quality control. The standard materials used in this calibration […]
Sysmex Corporation offers a new network solution, Caresphere,™ to provide new value through the intelligent use of information by people involved in testing and healthcare, with a view to accelerating the future use of information in healthcare. Caresphere™ creates an environment for linking and analyzing a variety of information from testing instruments and laboratory information […]
Sysmex Corporation celebrated the 50th anniversary of its establishment on February 20, 2018. We offer our heartfelt appreciation for the support of our customers and all other stakeholders since the time of our establishment in 1968.
Hamburg, Germany, 2018.01.16 – Sysmex Inostics, a global leader in blood based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology, today announces data from an abstract of a study comparing the performance of plasma RAS mutation detection by two commercial liquid biopsy testing platforms, OncoBEAM RAS CRC and Idylla ctKRAS Mutation Test. The […]
Sysmex Asia Pacific Pte Ltd, a subsidiary of Sysmex Corporation signed a distribution agreement with genedrive plc the near patient molecular diagnostics company, for its CE-marked Genedrive® HCV ID Kit and Genedrive® platform in the Asia Pacific region. This is genedrive’s second agreement signed with a subsidiary of Sysmex Corporation, a world leader in clinical […]
Colorectal cancer is the second most commonly occurring cancer in Malaysia (Malaysian National Cancer Registry Report 2007-2011). A new liquid biopsy testing to monitor the progression of metastatic cases of colorectal cancer is now available at Pantai Premier Pathology, Malaysia. The new liquid biopsy testing allows oncologists and surgeons to examine a ‘snapshot’ of the […]
The Dow Jones Sustainability Indexes are developed through collaboration between S&P Dow Jones Indices of the United States and Robeco SAM, a Swiss research specialist in the area of socially responsible investment. This year Sysmex has been selected for inclusion in the DJSI World for the second consecutive year.
Creating a System for Operating Mobile Pharmacies as a Disaster Response Measure – Sysmex Corporation, the Hyogo Pharmaceutical Society and Shinkai Transport Systems, Ltd. announce the signing of an agreement to cooperate on disaster relief activities, aimed at operating mobile pharmacies in times of disaster.
In order to continue supporting the initiatives of the GHIT Fund, which aims to assist in the application of Japanese technological innovation to healthcare in developing countries, we will be extending our provision of donations for a five-year period from 2018. By participating in the GHIT Fund, we will move forward with initiatives to develop […]
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) has opened a new R&D facility within its Kawasaki INnovation Gateway at SKYFRONT in the city of Kawasaki, Kanagawa Prefecture, to pursue R&D in bioinformatics, a key technology toward the realization of personalized medicine.
Sysmex Corporation has reached an agreement with Oxford Gene Technology IP Limited (“OGT”) to acquire all shares in OGT. Through this move, Sysmex aims to obtain OGT’s business and expertise in the cytogenetics1 domain and its reagent development capabilities used in next-generation sequencers (NGSs)2, thereby reinforcing its base in the life science business.